Goyal A, O’Leary D, Goyal K, et al. - Researchers investigated the risk of second malignancies in patients with cutaneous T-cell lymphoma (CTCL) via this systematic review and meta-analysis of manuscripts published between 1950-2019. They found 10 eligible studies, with 12 patient cohorts. Second malignancies were seen in 5.9-16.8% of patients. The majority of patients developing second malignancies were male, as demonstrated in all studies. The range for time between the diagnosis of CTCL and second malignancy was from 2.1-5.4 years. Findings displayed a greater risk of second malignancies, particularly Hodgkin and non-Hodgkin lymphoma, lung cancer, bladder cancer, and melanoma, in patients suffering from CTCL. The morbidity burden of second malignancies may be attenuated by early detection.